Hematology & Oncology Doctors in Sequim, WA Accepting Medicare
3 Hematology & Oncology doctors found. Showing 1 - 3
 Dr. Thomas J Fitzgerald, MD PH D Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 844 N 5th Ave, Sequim, WA 98382 Phone: 360-683-9895 Fax: 360-582-5614 |
Ahmer Younas, MD Internal Medicine - Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 844 N 5th Ave, Sequim, WA 98382 Phone: 360-683-9895 Fax: 360-582-5614 |
Dr. Binay Kumar Shah, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 844 N 5th Ave, Sequim, WA 98382 Phone: 360-683-9895 Fax: 360-582-5614 |
News Archive
Redesigned version of CTC-Chip effective in capturing rare circulating tumor cells
A redesigned version of the CTC-Chip a microchip-based device for capturing rare circulating tumor cells (CTCs) appears to be more effective and should be easier to manufacture than the original. Called the HB-(herringbone) Chip, the new device also may provide more comprehensive and easily accessible data from captured tumor cells.
New web-based tool developed to aid health professionals determine right treatment for injured workers
University of Alberta researchers have developed a new web-based tool to aid health professionals in determining the right treatment course for injured workers, helping them feel better and get back to work earlier.
Dermatologist offers 5 grooming essentials for men to make skin healthy and glow
If you're short on holiday gift ideas for men this season, consider a grooming product. Contrary to popular belief, a growing number of men are requesting recommendations for skincare products, says Natalie Semchyshyn, M.D., assistant professor of dermatology at Saint Louis University.
Repligen receives USPTO Notice of Allowance for patent covering a recombinant form of Protein A
Repligen Corporation announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering a recombinant form of Protein A which is identical in structure to the commercial form of Protein A from Staphylococcus aureus which is used in the production of many of the world's approved monoclonal antibodies. The patent, which will remain in force until 2028, covers a new Repligen proprietary product which is now available in commercial quantities.
› Verified 4 days ago
Family Medicine
Internal Medicine
Dermatology
Hematology & Oncology
Psychiatry & Neurology
Radiology
General Practice
Gastroenterology
Pulmonary Disease